About eterna therapeutics - ERNA
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.
ERNA At a Glance
Ernexa Therapeutics, Inc.
1035 Cambridge Street
Cambridge, Massachusetts 02141
| Phone | 1-212-582-1199 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -14,084,000.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ERNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.927 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.682 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.079 |
ERNA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,816,800.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ERNA Liquidity
| Current Ratio | 1.006 |
| Quick Ratio | 1.006 |
| Cash Ratio | 0.605 |
ERNA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -253.697 |
| Return on Equity | -686.689 |
| Return on Total Capital | -487.167 |
| Return on Invested Capital | -580.066 |
ERNA Capital Structure
| Total Debt to Total Equity | 20.408 |
| Total Debt to Total Capital | 16.949 |
| Total Debt to Total Assets | 8.399 |
| Long-Term Debt to Equity | 11.542 |
| Long-Term Debt to Total Capital | 9.581 |